184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL)

M Alsina,T Alekshun,C Mcisaac-Simonelli,M Kharfan-Dabaja,W Dalton,B Djulbegovic,H Fernandez,D.M Sullivan,E Ayala,T Field,D Garrett,W.E Janssen,B Maddox,L.E Perez,D Kettner,J Perkins,J Raychaudhuri,C.H Anasetti

doi:10.1016/j.bbmt.2007.12.193

184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL)

M Alsina, T Alekshun + Show 16 more

Open Access

https://doi.org/10.1016/j.bbmt.2007.12.193

Copy DOI

Journal: Biology of Blood and Marrow Transplantation	Publication Date: Jan 25, 2008
License type: cc-by-nc-nd

Affiliation: Moffitt Cancer Center

#Tandem Peripheral Blood Stem Cell #Primary Refractory Multiple Myeloma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL)

Full Text